SCHEMBL10003873

SCHEMBL10003873

Cc1ccc(S(=O)(=O)n2cc(Br)cc2C(=O)C(C#N)=CN(C)C)cc1

nearest known ligand 0.41

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ NPSR1 Q6W5P4 2/20 0.41
▸ CA1 P00915 1/20 0.38
▸ CA2 P00918 1/20 0.38
▸ HPGD P15428 4/20 0.36
▸ LMNA P02545 2/20 0.35
▸ RAB9A P51151 2/20 0.34
▸ L3MBTL1 Q9Y468 1/20 0.34
▸ MAPT P10636 2/20 0.34
▸ RECQL P46063 1/20 0.34
▸ ALDH1A1 P00352 3/20 0.33
▸ KMT2A Q03164 1/20 0.33
▸ KDM4E B2RXH2 1/20 0.33
▸ UBE2N P61088 1/20 0.33
▸ GAA P10253 1/20 0.33
▸ KDM1A O60341 1/20 0.33
▸ PKM P14618 1/20 0.32
▸ SMN1; SMN2 Q16637 1/20 0.32
▸ CYP2C9 P11712 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10003870 1.00 NPSR1 (0.41) NPSR1CA1CA2HPGDLMNA
SCHEMBL10003402 0.81 RAPGEF4 (0.42) NPSR1CA1CA2HPGDLMNA
SCHEMBL10003399 0.81 RAPGEF4 (0.42) NPSR1CA1CA2HPGDLMNA
SCHEMBL16178030 0.81 NPSR1 (0.38) NPSR1HPGDLMNARAB9AL3MBTL1
SCHEMBL16178031 0.81 NPSR1 (0.38) NPSR1HPGDLMNARAB9AL3MBTL1
SCHEMBL10003655 0.79 ALOX5 (0.43) NPSR1HPGDLMNAALDH1A1
SCHEMBL10003661 0.79 ALOX5 (0.43) NPSR1HPGDLMNAALDH1A1
SCHEMBL10003003 0.79 ALOX5 (0.43) NPSR1HPGDLMNAL3MBTL1MAPT
SCHEMBL10003002 0.79 ALOX5 (0.43) NPSR1HPGDLMNAL3MBTL1MAPT
SCHEMBL10003855 0.77 NPSR1 (0.37) NPSR1HPGDLMNARAB9AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2471786-B1 AMINOPYRAZOLE DERIVATIVE CHUGAI PHARMACEUTICAL CO LTD (JP) 2015-11-04 — — EP disclosed
US-8829199-B2 Aminopyrazole derivative CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2014-09-09 — — US disclosed
US-8829199-B2 Aminopyrazole derivative CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2014-09-09 — — US disclosed
US-20120208811-A1 Aminopyrazole Derivative F. HOFFMANN-LA ROCHE AG (CH) 2012-08-16 — — US disclosed
US-20120208811-A1 Aminopyrazole Derivative F. HOFFMANN-LA ROCHE AG (CH) 2012-08-16 — — US disclosed
EP-2471786-A1 AMINOPYRAZOLE DERIVATIVE Chugai Seiyaku Kabushiki Kaisha (JP) 2012-07-04 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120208811-A1 Aminopyrazole Derivative FGFR1, FGFR3, FGFR4 NPSR1 1710/4885CA1 3953/4885CA2 466/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback